Amgen and Immatics Biotechnologies GmbH, have entered a research collaboration and exclusive license agreement to develop next-gen T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Immatics’ XPRESIDENT target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the goal of creating new oncology drugs. Amgen will be responsible for the clinical development, manuf...